nasdaq:aezs
|
521171
|
Apr 21st, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 20th, 2024 10:46PM
|
Apr 20th, 2024 10:46PM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|
nasdaq:aezs
|
521171
|
Apr 20th, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 19th, 2024 10:37PM
|
Apr 20th, 2024 04:29PM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|
nasdaq:aezs
|
521171
|
Apr 19th, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 18th, 2024 10:45PM
|
Apr 18th, 2024 10:45PM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|
nasdaq:aezs
|
521171
|
Apr 18th, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 17th, 2024 10:45PM
|
Apr 18th, 2024 05:49PM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|
nasdaq:aezs
|
521171
|
Apr 17th, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 16th, 2024 10:35PM
|
Apr 17th, 2024 02:13PM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|
nasdaq:aezs
|
521171
|
Apr 16th, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 15th, 2024 10:34PM
|
Apr 16th, 2024 10:29AM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|
nasdaq:aezs
|
521171
|
Apr 15th, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 14th, 2024 10:36PM
|
Apr 15th, 2024 04:10PM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|
nasdaq:aezs
|
521171
|
Apr 14th, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 13th, 2024 10:30PM
|
Apr 14th, 2024 10:30AM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|
nasdaq:aezs
|
521171
|
Apr 13th, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 12th, 2024 10:21PM
|
Apr 13th, 2024 10:57AM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|
nasdaq:aezs
|
521171
|
Apr 12th, 2024 12:00AM
|
AEterna Zentaris Inc.
|
1.8K
|
40.00
|
Open
|
|
Apr 11th, 2024 10:24PM
|
Apr 12th, 2024 07:52AM
|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
|
Open
|
Endocrinology and Orphan Products
|
Open
|
315 Sigma Drive
|
Charleston
|
South Carolina
|
US
|
29486
|
|
AEterna Zentaris
|
|
Health Care Equipment & Services
|